Close Menu

Breaking News

The group wants the agency to allow labs to discuss gene-drug relationships with "adequate evidence" in test reports and hold a public meeting.

The companies said the commercial partnership will help increase access to genomic information in the community oncology setting.

The AlloSeq cfDNA kit is used to quantify the level of donor-derived cell-free DNA in transplant recipients in order to measure graft health.

The new complaints add to related patent suits Illumina filed against BGI last year in the US, Germany, Switzerland, and Turkey.

The firm said it will use the funds to advance development of its HostDx immune response gene expression tests for acute infections and sepsis.

The oncology division of Human Longevity performs next-generation sequencing services for pharmaceutical customers and generated $10 million in revenue in 2019. 

The Church Lab spinout has now raised more than $50 million to develop and commercialize its fluorescent in situ sequencing technology for spatial genomics.

Quidel said that it expects fourth quarter 2019 revenues to be in the range of $151 million to $152 million, which would eclipse analyst expectations.

The firm also announced an exclusive distribution deal covering Israel for its T2 Resistance, T2Bacteria, and T2Candida panels

The company said it delivered 4,480 DecisionDx-Melanoma test reports in Q4 2019 compared to 3,270 reports in Q4 2018.

The San Diego-based company plans to develop a flexible, modular, and high-performing sequencing platform based on proprietary technologies in different areas.

A genome-wide association meta-analysis involving almost one million heart failure cases and controls identified 11 risk loci and helped distinguish potential causal contributors.

The clinical study will evaluate a next-generation sequencing-based test, which has the potential to detect all known respiratory pathogens in 12 hours.

The San Diego firm has now raised at least $145 million to drive development of its DNA sequencing platform and build manufacturing and commercial operations.

The deal follows a number of recent acquisitions in the animal genomics space for Neogen including Canadian animal genomics firm Delta Genomics Centre.

The additional funds follow the $25 million that the company announced in May 2019, bringing the total figure for the round to $45 million.

The multi-center registry study aims to measure the clinical impact of serial testing with Signatera in patients with stage II or stage III colorectal cancer.

The investigators used gene expression, chromatin interaction, and functional annotations to prioritize 191 genes as targets of potentially causal variants.

The magistrate did recommend that the court dismiss two counts made against Natera with respect to trademark disparagement and unfair trade practices.

Researchers discovered a duplication affecting the RYR2 gene in two families, which may indicate that it is a founder mutation in the Amish population.

Some of these shared loci were associated with higher BMI, but some were linked to lower BMI, particularly those also linked to schizophrenia.

The Durham, North Carolina-based startup will use the funds to develop a library preparation kit for single-cell sequencing.

In a large group of participants followed for decades, baseline body mass index outperformed a SNP-based obesity risk score for predicting midlife weight.

The firm said its panel, which runs on its MDx-3000 system, tests nasopharyngeal swabs for the most common viruses and bacteria.

Pages

The Hastings Center's Erik Parens argues in a Scientific American opinion piece that the current pandemic underscores the need to reconsider the hope placed in genomic medicine. 

The Los Angeles Times writes that Operation Warp Speed has an ambitious timeline for developing a COVID-19 vaccine.

The Sydney Morning Herald reports that Australia is launching its trial of preconception carrier testing Tuesday.

In PNAS this week: autosomal genes commonly affected by loss-of-function variants, variants implicated in testis development disorders, and more.